Almost half of patients who died with inflammatory bowel disease (IBD) died prematurely, and artificial intelligence (AI) can predict these premature deaths, according to new data. In a population ...

They compared the risk for IBD between patients with psoriasis or ankylosing spondylitis who initiated IL-17A inhibitors and those who initiated apremilast between January 2015 and December 2024.